web 2086 has been researched along with Chronic Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imoto, K; Kato, M; Miyaji, S; Miyake, H; Nakamura, M; Oda, T | 1 |
| Giers, G; Janzarik, H; Kempe, ER; Mueller-Eckhardt, C | 2 |
3 other study(ies) available for web 2086 and Chronic Disease
| Article | Year |
|---|---|
Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs.
Topics: Administration, Topical; Animals; Azepines; Chronic Disease; Conjunctiva; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Eosinophil Peroxidase; Eosinophils; Guinea Pigs; Male; Ophthalmic Solutions; Ovalbumin; Platelet Activating Factor; Tears; Triazoles | 2004 |
PAF-acether-antagonist WEB 2086 for treatment of chronic idiopathic thrombocytopenia.
Topics: Azepines; Chronic Disease; Drug Evaluation; Humans; Platelet Activating Factor; Thrombocytopenia; Triazoles | 1990 |
Failure of the platelet-activating-factor antagonist WEB 2086 BS for treatment of chronic autoimmune thrombocytopenia.
Topics: Adult; Aged; Autoimmune Diseases; Azepines; Chronic Disease; Drug Evaluation; Female; Humans; Male; Middle Aged; Platelet Activating Factor; Prospective Studies; Thrombocytopenia; Triazoles | 1990 |